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S U M M A R Y
Objectives: The acute manifestations of dengue are well known. The clinical symptoms that present
during the convalescent phase of infection are less well characterized, but may be autoimmune-based.
This study was undertaken to determine the prevalence of persistent clinical symptoms among
individuals infected during the 2006 Cuban epidemic and to evaluate the immunological and genetic
factors associated with their occurrence.
Methods: In 2008, clinical data and blood samples were collected from a random sample of adult
individuals diagnosed during the 2006 epidemic with dengue fever (DF, n = 68), dengue hemorrhagic
fever (DHF, n = 29), or an asymptomatic infection (AI, n = 42). The presence of persistent symptoms was
evaluated in all individuals and a psychological assessment was performed. IgG titers and the Fc receptor
(FcR) were also evaluated. The following autoimmune markers were assessed in a subset (n = 26) of
symptomatic individuals: complement factors C3/C4, rheumatoid factor (RF), C-reactive protein (CRP),
antinuclear antibodies (ANA), and immune complex (IC).
Results: Over half (55/97) the individuals with a prior of diagnosis of DF or DHF had persistent clinical
symptoms in the 2 years following infection. The sequelae were unrelated to the initial diagnosis and
were more common among women (44/55). No symptoms were reported in the AI group and all study
participants had normal mental and cognitive function. Persistent clinical symptoms were associated
with HH polymorphic variant (p = 0.027) and high IgG titer (p = 0.041). Autoimmune marker alterations
were common (20/26) in the subset of symptomatic individuals evaluated.
Conclusions: Clinical sequelae after recovery from an acute dengue virus infection are common in the 2
years following infection. The results obtained in this study suggest that persistent symptoms are
associated with alterations in some immunological parameters and FcgRIIa gene polymorphism. This
could suggest an autoimmune-based disturbance.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Dengue is a mosquito-borne viral disease endemic in tropical
and subtropical countries that has emerged as a serious
international public health threat with almost half of the world’s
population at risk of infection.1 Infection with any of the four
serotypes (DENV-1–DENV-4) of dengue virus (DV) can produce a
broad spectrum of symptoms, ranging from asymptomatic
infection to a severe life-threatening illness. Symptomatic dengue* Corresponding author. Tel.: +53 7 2020450; fax: +53 7 2046051/2020633.
E-mail address: gmd@ipk.sld.cu (G. Garcı´a).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.09.008illness is typically classiﬁed into dengue fever (DF), a self-limiting
febrile illness, or a more severe form, dengue hemorrhagic fever
(DHF)/dengue shock syndrome (DSS).2
Several hypotheses for the pathogenesis of dengue virus
infection have been proposed. Among them, antibody-dependent
enhancement (ADE) of infection has long been thought to play a
central role.3 This phenomenon is based on cross-reactive non-
neutralizing antibodies in the serum of infected individuals, which
enhance viral entry of different dengue serotypes via the Fc
receptor (FcR), and worsen the disease severity. Importantly, the
FcRs are a family of membrane-bound glycoproteins expressed on
the surface of a range of leukocytes, which mediate a wide variety
of physiological and biochemical responses. The most widelyses. Published by Elsevier Ltd. All rights reserved.
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responses triggered by immune complexes (IC). Disruption of their
function due to polymorphism contributes to changes in antibody-
mediated responses involved in the development of autoimmune
diseases. In this capacity, increased expression of activating FcR,
including FcgRIIa, on monocytes and macrophages has been
associated with a subsequent increase in production of inﬂamma-
tory cytokines.4
While the acute manifestations of dengue are well
known,5 only a limited number of studies have reported the
unique clinical manifestations occurring during the early
convalescent phase of infection, which may have an autoim-
mune component in their development.6–9 Further, the long-
term consequences of the cross-reactivity of dengue antibodies
and their effect on plasmin activity,10 which may increase the
long-term risks of hemorrhage among infected patients, also
remain unknown.
This study was undertaken to evaluate the sequelae of dengue
disease in the 2 years following infection. Given the mediating
effect of the FcR in symptomatic dengue disease11,12 and its role in
the development of autoimmune disorders,13 we also carried out
additional immunological and genetic analyses to ascertain
whether persisting clinical manifestations among infected indi-
viduals are associated with alterations consistent with an
autoimmune-based disorder.
2. Materials and methods
2.1. Samples
This study was approved by the World Health Organization
(WHO) Special Programme for Research and Training in Tropical
Diseases (TDR) and the Tropical Medicine Institute ‘‘Pedro Kourı´’’
(IPK) ethics and scientiﬁc committees. Ninety-seven individuals
hospitalized at IPK during the epidemic with a conﬁrmed DENV-4
infection14 were randomly selected from the clinical charts and
recruited to participate in the study. Among them, 67 were female
and 30 were male. All the individuals included in the study were
adults, ranging between 32 and 60 years of age.
Of the 97 patients, 68 were classiﬁed as DF and 29 as DHF/DSS
according to the World Health Organization clinical classiﬁca-
tion.15 For all study participants, the initial dengue infection had
been established by anti-dengue-speciﬁc IgM detection in sera
collected in the ﬁrst 6 days of the acute illness.16
In addition, a sample of 42 patients with an asymptomatic
dengue infection, randomly selected from a seroepidemiological
study performed during the epidemic, were also included in the
study to ascertain the long-term clinical manifestations of
asymptomatic disease. Dengue infection during the 2006 epi-
demic was established in these individuals by the presence of
anti-dengue IgM and a high titer of anti-dengue IgG (1280), in
the absence of clinical symptoms (Pupo et al., unpublished
data).16,17
Prior to study recruitment, informed consent was obtained
from all study participants. As part of the study, each participant
provided a blood sample and was interviewed by trained
personnel. A standardized questionnaire was used to record
demographic characteristics and clinical information in order to
evaluate the persistence of clinical symptoms such as fever,
headache, retro-ocular pain, insomnia, alopecia, myalgia, ar-
thralgia, asthenia, anorexia, dizziness or poor appetite, nausea,
vomiting, itch, and bleeding (vaginal bleeding, epistaxis)9 in the 2
years since infection. A psychological evaluation was also
performed on all individuals to assess physical and mental
ability, motor activity, speaking ability, mood, and cognitive
processes.2.2. Immunological and genetic correlative studies
In addition to the clinical data, blood samples acquired at the
time of recruitment were immediately separated for anti-dengue
IgG titer analysis and neutralizing antibody assays, as well as
genetic (FcgRIIa) studies.
2.3. ELISA inhibition method to detect IgG anti-dengue
The ELISA inhibition method (EIM) was followed, as previously
described.16 Brieﬂy, polystyrene plates (Costar) were adsorbed
with human anti-dengue IgG after blocking, and dengue-4 antigen
previously diluted 1/40 in phosphate-buffered saline (PBS) plus
0.05% Tween 20 was added to each well. Serum samples diluted
from 1/20 to 1/10 240 were tested. Volumes of 100ml of each
sample were added. Human IgG anti-dengue peroxidase conjugate
diluted 1/3000 in PBS plus 0.05% Tween 20 and 2% fetal bovine
serum were added. Substrate containing ortho-phenylenediamine
(OPD) was added. The reaction was stopped after a 30-min
incubation and the test was read at 492 nm. The percent inhibition
was calculated as: inhibition % = [1  (OD sample/OD negative
control)]  100, where OD is the optical density. The antibody titer
for each sample was considered as the highest dilution with a
percentage of inhibition 50%.
2.4. Genomic studies
Genomic DNA was extracted from the whole blood using a
Qiagen DNA extraction kit, and stored at 20 8C for further
genomic analysis. To determine the polymorphism associatedwith
FcgRIIa, the protocol used by Bazilio et al. was employed.18 The
polymerase chain reaction (PCR) was carried out to amplify the
genetic region of interest using previously published oligonucleo-
tide primers.14 Speciﬁcally, a 1-kb portion of the FcgRIIa gene,
containing exon 4 and part of exon 5, separated by an intron, was
ampliﬁed by PCR using sense primer P63 (50-CAAGCCTCTGGT-
CAAGGTC) and antisense primer FcgRII-30 (50-CAATGACCACAGC-
CACAA TC). Nested PCR was performed using the speciﬁc sense
primers, 494A and 494G (50-ATTCTCCC[A/G]TTTGGATC), respec-
tively, and P52 as antisense primer (50-GAAGAGCTGCCCATGCTG).
PCR products were run on agarose gel in a DNA electrophoresis,
and the allelic forms of the FcgRIIa gene were identiﬁed for each
sample.
2.5. Autoimmune markers
2.5.1. Antinuclear antibodies (ANA)
ANA tests were performed using indirect immunoﬂuorescence
microscopy. Brieﬂy volumes of 50 ml of serum samples diluted 1/
10 in 1 PBS were added over the slide with rat liver tissue
previously ﬁxed in acetone. After 30 min incubation, 50 ml of
human IgG antihuman ﬂuorescein conjugate (Wellcome, #
k648120) diluted 1/20 in Evan’s bluewere added. After incubation
under the same conditions, the slides were evaluated under a
ﬂuorescence microscope (Leite Diaplan) and results were
reported as positive if the tissue showed an immunoﬂuorescence
pattern.19
2.5.2. Precipitation of serum antigen–antibody immune complexes in
polyethylene glycol
The IC detection test was performed using a turbidimetric
assay. Brieﬂy, the serum samples diluted one half in borate buffer
0.1 M, pH 4 were mixed with polyethylene glycol (PEG) buffer.
After 60 min at 21–25 8C of incubation, each sample was read
photometrically at 450 nm and the results were evaluated using
the index of positivity (IP) or in units of ‘absorbance of sample in
Table 1
Clinical manifestations reported by individuals suffering clinical dengue in 2006
Havana epidemic, two years after their acute illness
Clinical manifestation Number of patients (%)
Muscle pain 42 (30.2%)
Arthralgia 41 (29.5%)
Asthenia 32 (23.0%)
Hand weakness 31 (22.3%)
General malaise 28 (20.1%)
Irritability 27 (19.4%)
Lost of memories 27 (19.4%)
Palpitations 27 (19.4%)
Dizziness 25 (17.9%)
Arthropathy 24 (17.3%)
Headache 21 (15.1%)
Retroocular pain 20 (14.4%)
Anorexia 15 (10.8%)
Alopecia 13(9.3%)
Rash 12(8.6%)
Nausea 10(7.2%)
Vaginal Bleeding 10(7.2%)
Diarrhea 8 (5.7%)
Gingivorrhagia 6(4.3%)
Vomiting 3(2.1%)
[(Figure_1)TD$FIG]
Figure 1. Relationship between anti-DV IgG and the presence of clinical
manifestations. Each box plot represents data from the highest IgG antibody
geometric mean titer (GMT) in individuals with persistence of clinical
manifestations (n = 55) or not (n = 42). The central horizontal line indicates the
median value, the box edges (hinges) the ﬁrst and third quartiles. The interquartile
range within the box includes the central 50% of values. The whiskers show the
maximum and minimum values.
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0.050 OD units was regarded as a normal level of IC.20
2.5.3. Complement factors C3 and C4, rheumatoid factor (RF), and C-
reactive protein (CRP)
Complement factors C3 and C4, RF, and CRPwere determined by
immunoturbidimetric automatic test using the commercial kits
Tina-quant C4, Tina-quant C3c, Cobas, Tina-quant RF II, Cobas, and
Tina-quant CRP, Cobas, respectively, for the automatic analyzer
Roche Hitachi (Hitachi 912 automatic analyzer).
2.6. Assessment of neutralizing antibodies to dengue virus
The presence of neutralizing antibodies to the four DENV
serotypes was assessed by plaque reduction neutralization
technique (PRNT), according to Morens et al.,21 with slight
modiﬁcations.22
A subset of samples from 2006 epidemic patients with clinical
dengue and persistent manifestations (n = 26) were assayed
simultaneously on BHK21 cells. A 100ml volume of a single
dilution (1/30) was incubated at 37 8C for 1 h with 100 ml of a
working dilution of virus calculated to give 10–20 pfu/50ml in the
ﬁnal volume of virus–serum mixture. After incubation, 50 ml of
virus–serum mixture was added to 0.5 ml of BHK21 suspension
(1.5  106 cells) in each of three wells of a 24-well polystyrene
plate. After 4 h incubation at 37 8C in a CO2 atmosphere, 0.5 ml of
3% medium viscosity carboxymethyl cellulose made up in Eagle’s
minimumessentialmedium (EMEM)with 10%Heated Fetal Bovine
Serum (HFBS), 1% L-glutamine 2 mM, and 100 U of penicillin plus
100 mg/ml streptomycin was added to each well. Plates were
incubated in 5% CO2 at 37 8C for 5–7 days before the addition of
stain. An immune mouse ascites ﬂuid (strain H87; Centers for
Disease Control and Prevention (CDC), Atlanta, GA, USA) was
employed as positive control and one human serum without
antibodies to DV as negative control. Sera showing a 50%
reduction in the number of plaques versus the control virus
plaques were considered positive. The immune status of individu-
als to virus serotypes presenting during the Havana dengue
epidemiological situations (DENV-1 in 1977, DENV-2 in 1981,
DENV-3 in 2001, and DENV-4 in 2006) was determined by means
of the neutralizing anti-dengue antibodies.23
2.7. Statistical analysis
The FcgRIIa genotypes (R/R131, H/H131, and R/H131) and
allelic frequencies in the studied individuals with symptomatic DV
infections in 2006 were compared by Chi-square test. The Fisher’s
exact test was used for small sample numbers. Differences in IgG
anti-dengue titer were analyzed using the Mann–Whitney test. A
one-sided p < 0.05 was considered to be statistically signiﬁcant.
Differences in persistence of clinical manifestations 2 years after
dengue infection between males and females were analyzed using
the Chi-square test. Data analyses were performed using SPSS
software version 11.5.1 (SPSS Inc., Chicago, IL, USA) and Epi Table
statistical analysis package (Epi Info, CDC, Atlanta, GA, USA).
3. Results
3.1. Medical and psychological interview results at 2 years after the
acute infection
In the 2 years following hospital discharge, more than half (55/
97, 56.7%) of the study participants reported having dengue
symptoms. The most frequently reported symptoms were related
to physical or mental exercising (Table 1). No clinical symptoms
were reported among study participants with asymptomaticinfections at the time of diagnosis. Emotional, social, and cognitive
functions were normal in all study participants, who all
demonstrated a favorable mental status on psychological evalua-
tion.
3.2. Relationship between clinical manifestations of cases and
demographic data
Among 97 individuals included in the study, 67 were female
and 30 were male. As shown in Table 2, the persistence of clinical
manifestations 2 years after dengue infection was signiﬁcantly
more prevalent among women (65.7% in women compared to a
Table 4
Evaluation of the autoimmunemarkers in 26 individuals with persisting symptoms
Autoimmune marker No. of individuals % Normal range
ANA 6 23.1 -
Borderline C3 2 7.7 90–180 mg/dl
Increased C4 3 11.5 10–40 mg/dl
IC 11 42.3 0.050 OD
RF 1 3.8 0–14 UI/ml
CrP 11 42.3 0.50 mg/dl
ANA, anti-nuclear antibodies; C3 and C4, complement factors 3 and 4; IC, immune
complex; RF, rheumatoid factor; CrP, C-reactive protein.
Table 2
Gender distribution associated with recovery of dengue clinical infection
Gender Symptoms Total
Yes No
Femalesa 44 23 67
Males 11 19 30
a Signiﬁcantly different from males, p=0.008 (Chi-square test).
[(Figure_2)TD$FIG]
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from their illness (p = 0.008). There were no other statistically
signiﬁcant differences in the demographic characteristics of study
participants with and without persistent symptoms.
3.3. Persistent clinical manifestations, anti-dengue IgG titer and their
relationship to the acute illness infection
No differences were detected between the initial clinical
presentation (DF or DHF/DSS) during the acute illness and
persistence of clinical manifestations 2 years after infection
(p = 0.086). However, higher titers of anti-dengue IgG antibodies
were seen in those with persistence of clinical manifestations
(p = 0.041, Figure 1). The predominant clinical manifestations
consisted of neurological complaints, as well as joint, muscle and
bone pain, showing no particular relationships with individual IgG
titers (data not shown).
3.4. The polymorphism of FcgRIIa and its association with persistent
clinical manifestations
Genotype frequencies of the FcgRIIa polymorphism did not
differ signiﬁcantly between study participants with and without
persisting clinical symptoms (p = 0.08, Table 3). Considering the
inﬂuence of the FcgRIIa in the development of autoimmune
diseases and our recent demonstration of the role of the FcgRIIa
polymorphism as an inherited risk factor in the pathogenesis of
DHF/DSS in Cubans (manuscript in preparation), comparisons
between lower and higher afﬁnity binding alleles among HH study
participants (HR and RR) were performed. It was found that the HH
genotype was associated with the presence of persistent symp-
toms (p = 0.027; odds ratio 2.83, 95% conﬁdence interval 1.01–
8.11; Table 3). Upon further analysis, the HH genotype was found
to be associated with joint, muscle or bone pain (p = 0.036) and
neurological complaints (p = 0.008, Fisher’s exact test).
3.5. Autoimmunity markers and their relationship with clinical
manifestations
We next sought to ascertain whether persistence of clinical
symptoms was related with autoimmune disorders. Using a
randomly selected subset of individuals with persistence of
symptoms (n = 26; DF = 18, DHF = 8), the following markers of
autoimmune disease were investigated: ANA, C3 and C4 comple-Table 3
The polymorphism of FcgRIIa and its association with the presence of clinical
symptoms
Genotype Presence of clinical symptoms Total
No symptoms Symptoms
HH 8 (26.7%) 22 (73.3%) 30
HR 23 (52.3%) 21 (47.7%) 44
RR 11 (47.8%) 12 (52.2%) 23
Total 42 55 97
Genotype distribution frequency in individuals with and without sequelae: Chi-
square p=0.08. Comparison between HH vs. HR+RR, p=0.027 (Chi square test).ment factors, IC, RF, and CRP. Twenty individuals (76.9%) showed
alterations in at least one marker (Table 4) and six out of 26
individuals (23.1%) showed ANA. Markers were not found to be
associated with the diagnosis at presentation (DF or DHF), possibly
due to the sample size. IC and CRP were found to be increased in
most samples (42.3%) and individuals with increased ICs had
elevated IgG titers, as compared to individuals with normal ICs
(p = 0.042, Figure 2).
3.6. Sequence of DV infection and a possible relationship with the
persistent clinical manifestations
The sequence of DV infection was analyzed in the 26
individuals in whom autoimmune markers were studied. This
analysis showed that most individuals (n = 21) had a history of
previous dengue infection, but even more importantly, most of
them a history of more than one dengue virus infection. Twelve
individuals had a history of tetravalent infection in the sequence
DENV-1-DENV-2-DENV-3-DENV-4 and four individuals pre-
sented a history of tertiary dengue infection, two in the sequence
DENV-1-DENV-2-DENV-4 and two in the sequence of DENV-1-
DENV-3-DENV-4. The other ﬁve individuals had had two
infections in the succession DENV-1-DENV-4 (n = 3) and DENV-
3-DENV-4 (n = 2). Only ﬁve individuals had had a primary
infection caused by DENV-4. These observations suggest that
having more than one dengue infection could be a trigger for this
potential autoimmune phenomenon.Figure 2. Relationship between anti-DV IgG antibodies and IC levels. Each box plot
represents data from the highest IgG geometric mean titer (GMT) in relation to
levels of immune complex (IC) in individuals with increased IC levels (n = 10) and
individuals with normal IC levels (n = 16). The central horizontal line in the box
indicates the median value, the box edges (hinges) the ﬁrst and third quartiles. The
interquartile range within the box includes the central 50% of the values. The
whiskers show the maximum and minimum values.
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Our study demonstrates that more than half of the study
participants diagnosed with symptomatic disease (either DF or
DHF) during the 2006 epidemic had persistence of some clinical
manifestations 2 years after infection. Interestingly, no persistent
symptoms were reported among people who were asymptomatic
following the initial infection in 2006. We also provide evidence
that suggests an association between persistent symptoms and the
FcgRIIa polymorphism, as well as some immunological abnormal-
ities. These ﬁndings constitute the ﬁrst demonstration in favor of
an autoimmune-based dengue pathogenesis.
A previous study described persistence of some of the dengue
symptoms up to 6 months after treatment in people who suffered
DHF.9 However, given the lack of a control group in the study (e.g.,
classical dengue cases or non-dengue cases), the symptoms
reported in the study could not be attributed to hemorrhagic
dengue.9 Other authors have also reported on a syndrome of post-
infectious fatigue that occurred in DHF and DF cases 2 months
following dengue infection.6 However, only hospitalized patients
with symptomatic infections were recruited into this study, such
that the sequelae of infection in asymptomatic patients could not
be assessed. Importantly, both of the above reports do, however,
provide evidence suggesting that dengue can result in prolonged
clinical disease following resolution of the acute phase of
infection.6,9
In our study, patients with persistent clinical manifestations
were predominantly female. This, combined with the types of
persistent symptoms, their relationship with IgG titers, and the
detection of autoimmune markers (CRP, IC and ANA) in a large
percentage of symptomatic individuals, points to the possibility of
an autoimmune phenomenon in this ‘post-dengue syndrome’.
Further, increased levels of CRP in cases with persistent symptoms
suggests a non-degenerative process, in which the damage is
immune-mediated. Presence of this acute phase protein may be
the result of a protracted stimulation by factors like interleukin
(IL)-6, IL-1, interferon (IFN)–a, –b and –g, and tumor necrosis
factor (TNF),5 possibly released as a result of the persistent
activation of FcgRIIa in the neutrophils, macrophages, and
dendritic cells by the IC.24
We only included adults in our study. However, it would also be
very interesting to look for dengue sequelae in children, since this
is an interesting and unexplored topic that should be taken into
account in future studies.
We performed no comparison between symptomatic and
asymptomatic participants in our study. It is therefore difﬁcult
to ascertain whether persistent clinical manifestations 2 years
after infection are actually associated with the development of
autoimmune disorders. Nevertheless, it should be noted that
autoimmune alterations were clearly evident in symptomatic
patients and occurred more frequently than would be expected in
the general population.
Given the essential role of FcR in phagocytosis of IC and in the
subsequent processing and modulation of antibody levels, FcR
dysfunction may disrupt immune regulation thereby exacerbating
or triggering autoimmune disease. Such disease-related FcR
dysfunction may include impaired IC clearance, altered regulation
of antibody production, and hypersensitivity to self-antigen/
antibody complexes.25 As such, the IC deposits may induce an
acute inﬂammatory reaction, clinically translated as inﬂammatory
pain in muscles and joints.4
Allelic variance of FcgRIIa with a single nucleotide polymor-
phism (SNP) changing amino acid 131, determines the binding
afﬁnity for IgG1.26,27 Arginine (R) at 131 results in an increased
ability to bind IgG1, while histidine (H) at 131 reduces binding of
IgG1.26,27 As a consequence of reduced binding of predominantIgG1 and IgG3 subclasses28 and decreased processing of circulating
ICs, the HH genotype variant commonly expressed in our
symptomatic individuals may further explain the persistence of
symptoms following infection. Speciﬁcally, failure to clear immune
complexes could lead to the ‘spontaneous’ development of disease,
as complexes accumulate over time andmay either be deposited in
a single organ or tissue, or in the circulation. Conversely, the
presence of RR genotype may be associated with recovery after
dengue infection, as a result of the efﬁcient control of antibody
production leading to IC elimination.29
Genetics and environmental factors, such as acute viral
infection, can induce transient autoimmune responses, including
the generation of auto-antibodies.30–32 In an acute DV infection,
anti-dengue NS1 antibody can cross-react with endothelial cells30–
33 and antibody can inhibit the active form of plasminogen through
molecular mimicry.10 Importantly, the development of Guillain–
Barre´ syndrome has been found to be associated with DV
infection,8 and IC deposition and retinal vasculitis have also been
reported during this infection.7
Collectively, it could be hypothesized that after DV infection,
cross-reacting antibodies IgG1 and IgG3 are generated. A failure to
properly clear the immune complexes due to FcgRIIa-131HH, may
then stimulate the release of pro-inﬂammatory cytokines, like
TNF-a and IL-1. These cytokines could then induce the synthesis of
acute phase proteins, which would further perpetuate the possibly
autoimmune-mediated clinical symptoms of dengue infection.
To the best of our knowledge, this study represents the ﬁrst
evidence of persistent symptoms following symptomatic (DF or
DHF) dengue disease, even at 2 years after infection. Combined
with the novel association of persistent symptoms with genetic
variants of FcgRIIa, the results of our study are of great relevance
for vaccine development.
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